Analyzes UK travel insurance market, highlighting post-COVID claims volatility, medical inflation impact, portfolio segmentation strategies, and scenario-based approaches to managing systemic reserving risks.
No subscription required · Instant access after purchase
This transcript examines the UK travel insurance market, where claims volatility has increased post-COVID due to disrupted travel patterns, rising medical inflation, and large-loss exposure. Insurers are adapting by segmenting portfolios across trip types and risk profiles, while separating high-severity medical claims for specialized modeling. Annual multi-trip policies dominate due to better risk visibility and renewals. Given the short-tail nature of the business, reserving relies on recent, relevant data, supplemented by scenario analysis to capture systemic risks such as pandemics and regional health events.
Experts are sourced from Nextyn’s verified network of 900,000+ professionals. All hold or previously held senior roles directly relevant to the topic — minimum VP level, typically C-suite or former C-suite.
Every transcript undergoes a two-pass MNPI review before listing. Material non-public information is redacted. All experts sign NDA and MNPI disclosure forms prior to the call. PII is fully anonymised.
Calls are conducted by trained Nextyn research moderators using a structured question guide. Sessions run 45–90 minutes. Verbatim transcription is produced within 24 hours with speaker labels and timestamps.
Final transcripts include an AI-assisted executive summary, tagged companies and tickers, expert metadata, and a compliance certificate. Delivered as a formatted PDF with instant download via Stripe.
Choose your expert profile, topic, and questions. We source, vet, conduct, and deliver. From $599.
Learn About Custom Transcripts →Every Transcript-IQ transcript is MNPI-screened, PII-redacted, and compliance-certified. Instant delivery. No subscription.
.png)
Expert call transcripts on demand. MNPI-screened, PII-redacted, and ready for your next investment decision. No subscription required.